These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35281926)

  • 41. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
    Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H
    Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database.
    Castillon G; Salvo F; Moride Y
    Drug Saf; 2019 Jan; 42(1):27-34. PubMed ID: 30121742
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L; Di Pietrantonj C; Rovaris M; Rigon G; Frau S; Berardo F; Gandini A; Longobardi A; Weinstock-Guttman B; Vaona A
    Cochrane Database Syst Rev; 2014 Jul; (7):CD009333. PubMed ID: 25062935
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database.
    Barbieri MA; Cutroneo PM; Baratelli C; Cicala G; Battaglia A; Santoro V; Andò G; Spina E
    J Clin Pharm Ther; 2021 Aug; 46(4):1027-1040. PubMed ID: 33646603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug-related deaths: an analysis of the Italian spontaneous reporting database.
    Leone R; Sottosanti L; Luisa Iorio M; Santuccio C; Conforti A; Sabatini V; Moretti U; Venegoni M
    Drug Saf; 2008; 31(8):703-13. PubMed ID: 18636789
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
    Brown JWL; Coles A; Horakova D; Havrdova E; Izquierdo G; Prat A; Girard M; Duquette P; Trojano M; Lugaresi A; Bergamaschi R; Grammond P; Alroughani R; Hupperts R; McCombe P; Van Pesch V; Sola P; Ferraro D; Grand'Maison F; Terzi M; Lechner-Scott J; Flechter S; Slee M; Shaygannejad V; Pucci E; Granella F; Jokubaitis V; Willis M; Rice C; Scolding N; Wilkins A; Pearson OR; Ziemssen T; Hutchinson M; Harding K; Jones J; McGuigan C; Butzkueven H; Kalincik T; Robertson N;
    JAMA; 2019 Jan; 321(2):175-187. PubMed ID: 30644981
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database.
    Leone R; Conforti A; Venegoni M; Motola D; Moretti U; Meneghelli I; Cocci A; Sangiorgi Cellini G; Scotto S; Montanaro N; Velo G
    Drug Saf; 2005; 28(6):547-56. PubMed ID: 15924506
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis.
    Prosperini L; Saccà F; Cordioli C; Cortese A; Buttari F; Pontecorvo S; Bianco A; Ruggieri S; Haggiag S; Brescia Morra V; Capra R; Centonze D; Di Battista G; Ferraro E; Francia A; Galgani S; Gasperini C; Millefiorini E; Mirabella M; Pozzilli C
    J Neurol; 2017 Feb; 264(2):284-294. PubMed ID: 27878443
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.
    Jalkh G; Abi Nahed R; Macaron G; Rensel M
    Vaccines (Basel); 2020 Dec; 9(1):. PubMed ID: 33375365
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; (6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reported Adverse Drug Reactions in Infants: A Nationwide Analysis in Malaysia.
    Rosli R; Dali AF; Aziz NA; Ming LC; Manan MM
    Front Pharmacol; 2017; 8():30. PubMed ID: 28239351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First French experience of ADR reporting by patients after a mass immunization campaign with Influenza A (H1N1) pandemic vaccines: a comparison of reports submitted by patients and healthcare professionals.
    Durrieu G; Palmaro A; Pourcel L; Caillet C; Faucher A; Jacquet A; Ouaret S; Perault-Pochat MC; Kreft-Jais C; Castot A; Lapeyre-Mestre M; Montastruc JL;
    Drug Saf; 2012 Oct; 35(10):845-54. PubMed ID: 22967189
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database.
    Soussan C; Gouraud A; Portolan G; Jean-Pastor MJ; Pecriaux C; Montastruc JL; Damase-Michel C; Lacroix I
    Eur J Clin Pharmacol; 2014 Nov; 70(11):1361-6. PubMed ID: 25183382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison.
    Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B
    Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identifying and Characterizing Serious Adverse Drug Reactions Associated With Drug-Drug Interactions in a Spontaneous Reporting Database.
    Magro L; Arzenton E; Leone R; Stano MG; Vezzaro M; Rudolph A; Castagna I; Moretti U
    Front Pharmacol; 2020; 11():622862. PubMed ID: 33536925
    [No Abstract]   [Full Text] [Related]  

  • 57. Descriptive analysis of adverse drug reaction reports in children and adolescents from Germany: frequently reported reactions and suspected drugs.
    Dubrall D; Leitzen S; Toni I; Stingl J; Schulz M; Schmid M; Neubert A; Sachs B
    BMC Pharmacol Toxicol; 2021 Oct; 22(1):56. PubMed ID: 34620231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse drug reactions in Nigerian children: a retrospective review of reports submitted to the Nigerian Pharmacovigilance Centre from 2005 to 2012.
    Obebi Cliff-Eribo K; Sammons H; Star K; Ralph Edwards I; Osakwe A; Choonara I
    Paediatr Int Child Health; 2016 Nov; 36(4):300-304. PubMed ID: 26384567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ototoxic Adverse Drug Reactions: A Disproportionality Analysis Using the Italian Spontaneous Reporting Database.
    Barbieri MA; Cicala G; Cutroneo PM; Mocciaro E; Sottosanti L; Freni F; Galletti F; Arcoraci V; Spina E
    Front Pharmacol; 2019; 10():1161. PubMed ID: 31649536
    [No Abstract]   [Full Text] [Related]  

  • 60. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.